Literature DB >> 28957783

Is sensitivity to daily stress predictive of onset or persistence of psychopathology?

T Vaessen1, M van Nierop2, J Decoster3, P Delespaul4, C Derom5, M de Hert3, N Jacobs6, C Menne-Lothmann4, B Rutten4, E Thiery7, J van Os8, R van Winkel2, M Wichers9, I Myin-Germeys2.   

Abstract

PURPOSE: The aim of the current study was to replicate findings in adults indicating that higher sensitivity to stressful events is predictive of both onset and persistence of psychopathological symptoms in a sample of adolescents and young adults. In addition, we tested the hypothesis that sensitivity to mild stressors in particular is predictive of the developmental course of psychopathology.
METHODS: We analyzed experience sampling and questionnaire data collected at baseline and one-year follow-up of 445 adolescent and young adult twins and non-twin siblings (age range: 15-34). Linear multilevel regression was used for the replication analyses. To test if affective sensitivity to mild stressors in particular was associated with follow-up symptoms, we used a categorical approach adding variables on affective sensitivity to mild, moderate and severe daily stressors to the model.
RESULTS: Linear analyses showed that emotional stress reactivity was not associated with onset (β=.02; P=.56) or persistence (β=-.01; P=.78) of symptoms. There was a significant effect of baseline symptom score (β=.53; P<.001) and average negative affect (NA: β=.19; P<.001) on follow-up symptoms. Using the categorical approach, we found that affective sensitivity to mild (β=.25; P<.001), but not moderate (β=-.03; P=.65) or severe (β=-.06; P=.42), stressors was associated with symptom persistence one year later. DISCUSSION: We were unable to replicate previous findings relating stress sensitivity linearly to symptom onset or persistence in a younger sample. Whereas sensitivity to more severe stressors may reflect adaptive coping, high sensitivity to the mildest of daily stressors may indicate an increased risk for psychopathology.
Copyright © 2017. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Epidemiology; Experience sampling method; Longitudinal; Prospective; Stress reactivity

Mesh:

Year:  2017        PMID: 28957783     DOI: 10.1016/j.eurpsy.2017.07.002

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  5 in total

1.  Experience sampling methodology in mental health research: new insights and technical developments.

Authors:  Inez Myin-Germeys; Zuzana Kasanova; Thomas Vaessen; Hugo Vachon; Olivia Kirtley; Wolfgang Viechtbauer; Ulrich Reininghaus
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

2.  Negative schizotypy attenuates the effect of momentary stress on social dysfunction related to COVID-19 social distancing.

Authors:  Michael D Masucci; Victoria Martin; Thanh P Le; Alex S Cohen
Journal:  Schizophr Res       Date:  2022-02-26       Impact factor: 4.662

3.  Polygenic liability for schizophrenia and childhood adversity influences daily-life emotion dysregulation and psychosis proneness.

Authors:  L-K Pries; B Klingenberg; C Menne-Lothmann; J Decoster; R van Winkel; D Collip; P Delespaul; M De Hert; C Derom; E Thiery; N Jacobs; M Wichers; O Cinar; B D Lin; J J Luykx; B P F Rutten; J van Os; S Guloksuz
Journal:  Acta Psychiatr Scand       Date:  2020-02-21       Impact factor: 6.392

Review 4.  A Review of Current Ambulatory Assessment Studies in Adolescent Samples and Practical Recommendations.

Authors:  Eeske van Roekel; Loes Keijsers; Joanne M Chung
Journal:  J Res Adolesc       Date:  2019-09

5.  The Leuven late life depression (L3D) study: PET-MRI biomarkers of pathological brain ageing in late-life depression: study protocol.

Authors:  Louise Emsell; Maarten Laroy; Margot Van Cauwenberge; Thomas Vande Casteele; Kristof Vansteelandt; Koen Van Laere; Stefan Sunaert; Jan Van den Stock; Filip Bouckaert; Mathieu Vandenbulcke
Journal:  BMC Psychiatry       Date:  2021-01-28       Impact factor: 3.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.